Sequenom (SQNM) Catching Bids at $5.75

go site Sequenom is finding price support today at $5.75, volume of 4.6M at 1p, after a severe three  day downdraft triggered by their earnings release. Net loss for Q4 was $18.4M on Revenues of $10.8M. Cash position is $42M. Some pundits didn’t like the inability of the Company to give a detailed financial outlook but that […]

Continue Reading 0

What’s Next for Helicos(HLCS)?

click Helicos made a timely entrance  in the race for genetic analysis systems with their HeliScope “true single molecule sequencer”  (tSMS), “the first DNA microscope”. The technology was positioned as an alternative to DNA amplification, requiring less starting material while eliminating  biases, complexity and errors.In addition,SMS technologies supposedly have the advantage of ultra long reads.An IPO […]

Continue Reading 0

Intermune(ITMN) up 60% on Panel Go-Ahead

go here The FDA Panel of lung experts voted 9-3 in favor of approval of Intermune’s drug perfenidone for idiopathic pulmonary fibrosis. The stock was 15 at the end of February(see raygent.com last week) and reached 37 after hours tonite.. The IBB (biotech ETF) should exceed a Five Year high tomorrow above 90 and is approaching the […]

Continue Reading 0

Why Healthcare Reform is So Difficult

There is a simple reason why healthcare reform is so hard to do-there has to be winners and losers. We have had  many months of discussion on how to pay for healthcare reform such as cuts in Medicare, concessions from Big Pharma, more competition across state lines, tax on “cadillac” insurance plans etc etc. And […]

Continue Reading 0

Biotech MoJo Risin’ with InterMune Surge

where can i buy vermox in uk The rally in biotech is back with lots of help from InterMune (ITMN).The stock was up over 60% to 23 this am after the Company posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee(PADAC) meeting to review the NDA for pirfenidone (Esbriet) for treatment of patients with idiopathic pulmonary fibrosis(IPF). IPF is a […]

Continue Reading 0

Medivation hangover -stock stable

Despite a bunch of way-too-late analyst downgrades (JPMorgan, Roth, Hapoalim) MDVN stock is up 1%+ at $13.25 on volume of 8.8M shares. But there are two interesting articles coming out of the Medivation drama: Robert Langreth writing in Forbes offers the potential of better results on two upcoming trials and comments from Lon Schneider, an […]

Continue Reading 0

Medivation Chills Biotech Sector

Medivation (MDVN) released disappointing Phase III results for its Alzheimer drug, known as dimebon, saying that the drug was ineffective in treating cognitive decline or behavioral disorders. The stock plunged 67% to 13 as of midday trading on Wednesday. In a joint release Medivation and its partner Pfizer (PFE) said its two Phase III trials […]

Continue Reading 0

Microfluidics (MFLU.OB) Update-Turnaround intact

Microfluidics announced Year-End 2009 and Q4 results yesterday and delivered numbers pretty much according to plan. Q4 Income was $80k; Gross margin at 60% Achieved $525k EBITA for Full Year; R&D was cut to $449k for Q4 but management says no impact on new products Generated $15.7M Revenue for 2009 a 6% increase for 2008; […]

Continue Reading 0

Clinical Diagnostics Part 2: market sector poised for growth

The drive to reduce healthcare costs and perform Comparative Effectiveness Research can get support from next generation diagnostic tests. A recent article by Bill Malone in Clinical Laboratory News, February 2010 Vol.36 No.2, presents an optimistic scenario for the In Vitro Diagnostics (IVD) Market. Referencing a report from the Embargo Group of Austin,Tx, a recent […]

Continue Reading 0

Clinical Diagnostics Part 1: a sector poised for growth

Many of the issues coming out of the  healthcare reform discussion:  rising medical costs, Medicare budget, need for better clinical outcomes, push for biogenerics have  caused concern among investors and limited returns in the healthcare sector. Although M&A activity has picked up, funding for venture start-ups. equity for public companies and IPOs’ is down to […]

Continue Reading 0